#ASCO21: Novartis flashes 'groundbreaking data' for $2B radioligand drug
Here’s the “groundbreaking” data from the prostate cancer drug Novartis spent $2 billion to acquire: The molecule hit every endpoint in the Phase III trial, including extending patient lives by 4 months compared to standard of care.
“It’s strikingly positive,” Oliver Sartor, a prostate cancer expert at Tulane who led the study, told Endpoints News. “During the course of the trial, you never really know how things are shaking out, and I was very, very pleasantly surprised.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.